Compare Supplements

INVESTIGATIONAL — no approved consumer dose. In the pivotal phase-2 obesity trial, once-daily oral tesofensine was studied at 0.25, 0.5 and 1.0 mg; 0.5 mg was identified as the best efficacy/tolerability balance. Not for self-administration; only appropriate within a clinical trial.

Morning

Oral tablet (investigational)

• Not an approved medicine — only appropriate within a clinical trial
• Cardiovascular disease, uncontrolled hypertension, arrhythmia or tachycardia (the heart-rate rise is a class concern)
• Psychiatric history — anxiety, mood disorders or insomnia (a Tesomet-related serious adverse event was exacerbated pre-existing anxiety)

• Serotonergic agents (MAOIs, SSRIs, SNRIs, triptans)
• Sympathomimetics / stimulants (phentermine, decongestants, caffeine in excess)
• Antihypertensives / heart-rate-lowering drugs